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The most lethal aspects of gastric adenocarcinoma (GA) are its invasive and metastatic properties. This aggressive phenotype remains
poorly understood. We have recently identified neuroepithelial cell transforming gene 1 (NET1), a guanine exchange factor (GEF), as
a novel GA-associated gene. Neuroepithelial cell transforming gene 1 expression is enhanced in GA and it is of functional importance
in cell invasion. In this study, we demonstrate the activity of NET1 in driving cytoskeletal rearrangement, a key pathological mechanism
in gastric tumour cell migration and invasion. Neuroepithelial cell transforming gene 1 expression was increased 10-fold in response
to treatment with lysophosphatidic acid (LPA), resulting in an increase in active levels of RhoA and a 2-fold increase in cell invasion.
Lysophosphatidic acid-induced cell invasion and migration were significantly inhibited using either NET1 siRNA or a RhoA inhibitor
(C3 exoenzyme), thus indicating the activity of both NET1 and RhoA in gastric cancer progression. Furthermore, LPA-induced
invasion and migration were also significantly reduced in the presence of cytochalasin D, an inhibitor of cytoskeletal rearrangements.
Neuroepithelial cell transforming gene 1 knockdown resulted in AGS cell rounding and a loss of actin filament organisation,
demonstrating the function of NET1 in actin organisation. These data highlight the importance of NET1 as a driver of tumour cell
invasion, an activity mediated by RhoA activation and cytoskeletal reorganisation.
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Gastric adenocarcinoma (GA) is the second most significant cause
of cancer-related deaths worldwide (Hohenberger and Gretschel,
2003). Tumour metastasis is the most lethal aspect of this disease,
whereby tumour cells spread to local or often distant lymph
nodes. Furthermore, lymph node involvement in GA greatly
affects disease prognosis and is associated with poor outcome
(de Manzoni et al, 2001; Hohenberger and Gretschel, 2003).
The invasive and metastatic abilities of these tumours and more
specifically the molecular mechanisms underpinning this aggres-
sive phenotype represent ideal targets for therapeutic intervention.
Tumour metastasis is a complex multistep process, involving
detachment of cells from the primary tumour, local invasion through
surrounding tissue and basement membrane, followed by intra-
vasation into the circulatory system and ultimately extravasation and
growth at distant organs. At the molecular level, tumour invasion
and metastasis is dependent on the complex interplay between key
biomolecules, including components of the extracellular matrix, cell
adhesion molecules and proteolytic enzymes, all of which contribute
to the pathological spread of tumour cells into neighbouring tissues
and extracellular spaces (Poste and Fidler, 1980). Regulation of the
tumour cell cytoskeleton to facilitate invasion is also an important
phenotypic change in metastatic tumour cells.
The motility of tumour cells is dependent on rearrangements
of the actin cytoskeleton for generating both protrusions and
retraction to generate a motility cycle resulting in net translocation
(Wang et al, 2005). Rho GTPases are an important family of
proteins that regulate the actin cytoskeleton. Modulation of Rho
activity promotes the metastasis of tumour cells by disrupting
epithelial-sheet organisation, increasing cell motility and promot-
ing the degradation of the extracellular matrix (Sander et al, 1998;
Sahai and Marshall, 2002).
We have recently identified enhanced NET1 expression in GA in
comparison with adjacent normal tissue and we have furthermore
shown NET1 to play a role in tumour cell invasion (Leyden et al,
2006). Neuroepithelial cell transforming gene 1 is a member of the
guanine nucleotide exchange factor (GEF) family, a group of
proteins that are known to activate and thereby regulate Rho
family members (Symons and Rusk, 2003; Rossman et al, 2005).
Although the roles of other GEFs in other cancers have been
established, the role of NET1 has not yet been elucidated. Other
GEFs with established roles in various malignancies include; ASEF,
which has been shown to promote the migration of colorectal
cancer cells (Kawasaki et al, 2003; Nathke, 2006); Bcr, which by
chromosome translocation and the formation of the Philadelphia
chromosome and the BcrAbl fusion protein is essential for
oncogenesis in human leukaemias (Advani and Pendergast,
2002). Another GEF, GEFH1, has been shown recently to be
transcriptionally responsive to mutant p53 that resulted in
increased tumour cell proliferation in a model of osteosarcoma
(Mizuarai et al, 2006). Although NET1 was originally identified as
an oncogene in neuroepithelial cells, its functional importance in
other malignancies has not yet been established (Chan et al, 1996).
Rho GTPases comprise a main branch of the Ras superfamily of
small (B21kDa) GTPases and function as bimolecular switches,
changing conformational states in response to either GDP or GTP
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sbinding. Rho proteins are inactive when bound to GDP and active
when GTP-bound, actively transducing signals by interaction
with downstream effector proteins (Bishop and Hall, 2000).
Binding to GTP and therefore activation is promoted by Rho–
GEFs and GTP hydrolysis, and therefore inactivation is catalysed
by Rho–GTPase-activating proteins (Rho–GAPs). Interestingly,
NET1 mRNA expression has been shown to be upregulated in
response to Helicobacter pylori infection, an established event in
gastric carcinogenesis (Chiou et al, 2001). In this study we aimed
to further characterise the role of NET1 in GA. The effect of NET1
knockdown on RhoA activation was assessed. Furthermore, the
effects of lysophosphatidic acid (LPA), a known activator of RhoA,
on NET1 expression and cell motility were also investigated. The
role of NET1 in LPA-induced RhoA activation and subsequent cell
motility was assessed. Likewise, the role of cytoskeletal rearrange-
ments in LPA-induced invasion and migration were investigated
and the effect of NET1 knockdown on the actin cytoskeleton
was also assessed. We aimed to characterise the function of
NET1 in the gastric tumour setting by defining the mechanism
underpinning its effect in promoting tumour cell invasion.
MATERIALS AND METHODS
Cell culture and cell treatments
AGS gastric cancer cell lines were cultured in Hams F12 medium
supplemented with 10% fetal bovine serum and grown under standard
conditions as previously described (Leyden et al, 2006). Throughout
this study, cells were treated with the following: 20mM LPA for 4h;
4mgml
 1 C3 exoenzyme for 4h or 5mM cytochalasin D (CyD).
Gene silencing by RNA interference
Neuroepithelial cell transforming gene 1 mRNA was silenced as
previously described (Leyden et al, 2006). Briefly, siRNA duplexes were
designed and synthesised for transiently silencing NET1, and a
chemically synthesised non-silencing siRNA duplex that had no known
homology with any mammalian gene was used to control nonspecific
silencing events (Qiagen Inc., Valencia, CA, USA). The sequences were
NET1 sense, 50-GGAGGAUGCUAUAUUGAUA-30;N E T 1a n t i s e n s e ,
50-UAUCAAUAUAGCAUCCUCC-30 and non-targeting sense, 50-UU
CUCCGAACGUGUCACGU-30;a n t i s e n s e ,5 0-ACGUGACACGUUCG
GAGAA-30. RNA interference was performed in six-well format
by seeding 3 10
5 cells per well. The effects of various doses of
siRNA on mRNA production were investigated (0, 17, 34 and
75nM) in a ratio of 1mg siRNA to 6ml to RNAifect (Qiagen) for
48h. RNA and protein were extracted and analysed as described
below. All RNA interference (RNAi) experiments were repeated in
triplicate. Separate RNAi treatments were performed to investigate
any cytotoxic effect, briefly, following RNAi treatment, viability
was assessed by trypsining and counting cells using Trypan blue
staining and a haemocytomoeter. To decipher any off target
effects, a second NET1 siRNA duplex was used with the following
sequence: sense, 50-GGUGUGGAUUGAUUGGAAA-30; antisense,
50-UUUCCAAUCAAUCCACACC-30.
Flow cytometry
The effect of RNAi on cell viability was assessed using flow
cytometry by staining with propidium iodide and Annexin V FITC.
Briefly, following knockdown, cells were trypsinised and washed
twice in ice-cold phosphate-buffered saline (PBS). A total of
1 10
5 cells were resuspended in 100ml binding buffer (10mM
HEPES/NaOH pH7.4, 140mM NaCl, 2.5mM CaCl2) to which was
added 5ml 2mgml
 1 Annexin V FITC and 10ml5 0 mgml
 1
propidium iodide. Following 15min incubation in the dark, flow
cytometry was performed using a Cyan ADP analyzer (Dako,
Dublin, Ireland) using 515/545nm filter set for FITC detection and
620/640nm set for propidium iodide. All analysis was repeated in
triplicate.
RNA extraction and PCR
TRIzolt (Sigma-Aldrich, Dublin, Ireland) was used to extract RNA
as previously described (Leyden et al, 2006). Following reverse
transcription, as previously described (Leyden et al, 2006)
real-time PCR was performed using a QuantiTectt SYBR Green
PCR Kit (Qiagen) following the manufacturers’ instructions.
Briefly, 2ml of cDNA template was mixed with 12.5ml SYBR Green
master mix containing Taq and dNTPs (Qiagen), 8.5ml DNase-free
water and 1ml each of forward and reverse primers. The sequences
of primers used for PCR were b-actin forward: 50-GTCACCTT
CACCGTTCCAG-30, reverse: 50-CTCTTCCAGCCTTCCTTCCT-30,
NET1 forward: 50-CTGTTCACCTCGGGACATTT-30, reverse: 50-TG
GAGCTGTCAGACGTTTTG-30. The reaction was carried out using
a Rotor Genet 3000 multiplex system. All measurements were
independently repeated three times. b-Actin mRNA expression
levels were used to normalise and compare expression values for
the genes of interest. The PCR products were separated on 1%
agarose gels and visualised under UV light.
Guanosine tri-phosphate-RhoA pulldown and immunoblot
analysis
Guanosine tri-phosphate-bound RhoA was detected using a
Rhotekin Rho-binding domain (RBD) ‘pull down’ assay (Upstate
Inc., Lake Placid, NY, USA). Following NET1 knockdown, media was
removed from cells before they were washed twice in ice-cold PBS
and lysed in ice-cold Mg
2þ lysis buffer (MLB) (Upstate Inc.). Cell
lysates were clarified by centrifugation at 14000g for 5min at 41C
and incubated with agarose-bound Rhotekin RBD beads (Upstate
Inc.) at 41C for 45min. The beads were pelleted by centrifugation and
washed three times in MLB before electrophoresis on a 13% SDS–
PAGE gel. Bound RhoA was detected by immunoblot using an anti-
Rho monoclonal antibody (Upstate Inc.). Likewise active RhoB and
RhoC levels were assessed using monoclonal antibodies ab53743 and
ab54837, respectively (Abcam plc, Cambridge, UK). The amount of
RBD-bound Rho was normalised to the total amount of Rho in total
cell lysates for the comparison of Rho activity (level of GTP-bound
Rho) in different samples. Neuroepithelial cell transforming gene 1
protein was detected using a monoclonal (H70) antibody (Santa Cruz
Inc., Santa Cruz, CA, USA) at a 1:500 dilution. b-Actin protein levels
were detected for use as a loading control using a monoclonal
antibody (Merck Biosciences, Nottingham, UK). Densitometric
analysis was performed using ImageJ 1.39u software (NIH, USA).
Using this software the density of the active Rho band was expressed
as a ratio to the density of the total Rho band.
Wound-healing migration assay
To investigate the migratory capacity of cells, cells were grown to
100% confluence in six-well plates in the presence of NET1-specific
or scrambled siRNA. The monolayer of cells were wounded by
performing a scratch with a sterile 10ml micropipette tip. Cells
were washed with sterile PBS, and fresh siRNA-containing media
was then added. Cells were photographed under  10 objective
lens at 24h. Carnoy software (Biovolution) was used to measure
the pixel width of the scratches.
In vitro trans-well migration and invasion
Briefly, Biocoat Matrigel 8-micron invasion chambers (BD
Biosciences, Bedford, MA, USA) were used to investigate the effect
of cell treatments on the in vitro invasiveness of the AGS gastric
cell line over 24h as previously described (Leyden et al, 2006).
Briefly, 5 10
5 cells were added to Biocoat Matrigel (BD
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24h under standard culture conditions. A chemo-gradient was
established by seeding cells in 1% serum and adding 20% serum to
the outer chamber. Invasive cells were fixed and stained using
methanol and haematoxilyn as previously described (Leyden et al,
2006). Invasive cells were counted in five  10 magnification
fields. Results were expressed as average cell count per field.
Similarly, cell migration was monitored using 8-micron inserts
without the inclusion of Matrigel.
Fluorescent staining of cytoskeleton components
Imunofluorescent staining for F-actin assembly was carried out
using rhodamine phalloidin (FAK100 kit from Chemicon Inter-
national Inc., Temecula, CA, USA). Cells were grown and treated as
detailed above. All growth medium was removed and cells were
washed three times for 5min with 0.05% (v/v) Tween-20 in PBS at
room temperature. Cells were fixed for 15min in 4% (w/v) p-
formaldehyde in PBS at room temperature. Cells were washed as
above and then permeabilised for 5min with 0.1% Triton X-100 (v/
v) in PBS at room temperature. Cells were washed and then
blocked for 30min with 1% (w/v) BSA in PBS at room temperature.
Following another wash step, labelling was achieved by incubating
for 1h with 0.12mgml
 1 tetramethyl rhodamine isothiocyanate
(TRITC)-conjugated phaloidin in PBS at room temperature in the
dark. Cells were washed as above, and slides were mounted using
an anitfade mounting solution (Cat no. 5013 from Chemicon
International Inc.). Fluorescent images were visualised using a
Zeiss Axioshop 40FL (Carl Zeiss Inc., Oberkochen, Germany).
Statistical analysis
Data are expressed as mean±s.d. from triplicate experiments and
were analysed with Microsoft Excel using a student’s t-test with
significance defined as Po0.05.
RESULTS
The effect of NET1 on RhoA activation, gastric cancer cell
migration and invasion
Loss-of-function experiments were carried out to determine the role
of NET1 activity in gastric cancer. An RNAi approach using an
siRNA duplex specifically targeting NET1 mRNA was used to
investigate the effect of NET1 knockdown on RhoA activation and
AGS gastric cancer cell migration and invasion. Neuroepithelial cell
transforming gene 1 mRNA production was dose–responsive to
siRNA, with 75nM siRNA causing 54% reduction in mRNA
expression (Po0.05), whereas non-targeting siRNA caused no
significant change in mRNA expression. (Figure 1A). This optimal
dose was used in further experiments. The PCR products were also
analysed by agarose gel electrophoresis (Figure 1B), where cells
t r e a t e dw i t h3 4a n d7 5n M NET1 siRNA displayed decreased levels of
NET1 mRNA in comparison with cells treated with the same
concentration of non-targeting siRNA. Western immunoblot con-
firmed reduced NET1 protein levels (Figure 1C, first panel). To
ensure RNAi treatments were non-cytotoxic, the viability of cells
undergoing all treatments were compared using Trypan blue staining
and cell counting. No significant differences were observed between
groups (data not shown). Furthermore, there was no significant
difference in cell viability numbers between 75nM control and NET1
siRNA groups as measured by flow cytometry using Annexin V-FITC
and propidium iodide staining (Supplementary Figure 1). Reduced
NET1 mRNA resulted in an attenuation of RhoA activation
(Figure 1C). The level of activated RhoA protein was dramatically
reduced in response to NET1 knockdown. Neuroepithelial cell
transforming gene 1 knockdown also caused a less dramatic decrease
in total RhoA levels. By expressing active RhoA as a ratio against
total RhoA using densitometric analysis, an 84% reduction (Po0.05)
in this ratio was observed in cells treated with NET1 siRNA
(Figure 1D). A second NET1 targeting siRNA duplex combination
also resulted in decreased levels of active RhoA (Supplementary
Figure 2). Knockdown of NET1 did not result in a change in the
levels of active RhoB or RhoC (Supplementary Figure 3).
The functional importance of NET1 in gastric cancer progres-
sion was displayed by a suppressive effect of NET1 knockdown
on AGS cell migration (Figure 2A). Using a wound-healing assay,
AGS cells in which NET1 knockdown was achieved were observed
to be less migratory than control cells (Figure 2A). There was no
significant wound healing in NET1 knockdown cells. After 24h,
control cells migrated and thereby reduced the wound width by
42% (Po0.005), where NET1 knockdown cells migrated and
reduced the wound width 9% (Figure 2B). Using the trans-well
system, 81% decreased in vitro migration and 94% decreased
invasion was observed in AGS cells in which NET1 knockdown had
been achieved (Po0.05) (Figure 2C and D).
The role of RhoA activation in NET1-mediated gastric
cancer cell migration and invasion
Having shown a relationship between NET1 expression and RhoA
activity, the effect of LPA, a known activator of RhoA, on NET1
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Figure 1 Decreased NET1 results in a reduction in the level of active
RhoA. (A) Dose–response of NET1 mRNA expression to increasing levels
of siRNA. Real-time PCR of NET1 mRNA expression in AGS cells
following treatment with 0, 17, 34 or 75nM non-target (NT) or NET1-
specific siRNA in six-well format. (B) Agarose gel analysis of NET1 and
b-actin PCR products in samples treated with or without increasing doses
of NET1 or non-target (NT) siRNA. (C) Western blot analysis of control
and RNAi-treated AGS cells. First panel: western immunoblot analysis of
NET1 protein. Second and third panel: ‘active’ and total RhoA, respectively.
Fourth panel: b-actin (loading control). (D) Ratio of active RhoA: total
RhoA protein in control and NET1 siRNA samples, as determined using
densitometric analysis. (*Po0.05). Error bars represent standard deviation
of triplicate experiments.
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sexpression was investigated. Lysophosphatidic acid was shown to
increase NET1 mRNA expression in a dose-dependent manner
in AGS gastric cancer cells (Figure 3A). Likewise, treatment
with LPA resulted in a dose-dependent increase in NET1 protein
levels (Figure 3B). Treatment with 20mM LPA was chosen for
subsequent analysis and it resulted in a 10-fold significant increase
in NET1 mRNA expression (Po0.05) (Figure 3A). Using a 12h
wound-healing scratch assay to monitor cell migration, treatment
with LPA was shown to result in 78% wound healing (Po0.005) in
comparison with control cells in which 12% healing was achieved
(Po0.05) (Figure 3C and D). Lysophosphatidic acid-induced
expression of NET1 was blocked by siRNA-mediated knockdown
of NET1 (Figure 4A). Treatment with LPA was insufficient at
restoring normal levels of NET1 in cells in which NET1 knockdown
had been achieved. Inhibition of RhoA activation with C3
exoenzyme did not effect LPA-driven NET1 expression and
furthermore C3 exoenzyme alone had no effect on NET1
expression (Figure 4A).
The above strategy was used to delineate the activation status of
RhoA in AGS cells. Treatment of AGS cells with LPA resulted in a
significant increase in NET1 mRNA expression (Po0.05)
(Figure 4A) with associated increase in the amount of active RhoA
protein, while not affecting the level of total RhoA protein
(Figure 4B). Lysophosphatidic acid was shown to increase the
levels of active RhoA in AGS gastric cancer cells (Figure 4B).
Further to our finding that NET1 knockdown resulted in a
reduction in the level of active RhoA (Figure 1C), the activation of
RhoA by LPA was also inhibited in cells in which RNAi-mediated
knockdown of NET1 mRNA was achieved (Figure 4B). Although
LPA in the presence of C3 exoenzyme resulted in increased
NET1 expression, this same treatment resulted in an inhibition of
RhoA activation (Figure 4B). Treatment of cells with C3
exoenzyme resulted in a complete inhibition of RhoA activation
(Figure 4B).
The effects of altered NET1 and RhoA levels on tumour cell
chemotaxis were examined in vitro. Using a 12h wound-healing
scratch assay to monitor cell migration, treatment with LPA was
shown to result in 78% wound healing (Po0.005) in comparison with
control cells in which 12% healing was achieved (Po0.05) (Figure 3C
and D). Treatment with LPA induced a 70% increase in AGS gastric
cancer cell migration and 100% increased invasion in vitro (Po0.05)
(Figure 4C and D). Knockdown of NET1 significantly reduced the level
of LPA-mediated chemotaxis. Lysophosphatidic acid-induced migra-
tion was reduced by 88% and LPA-induced invasion was reduced by
93% in cells in which NET1 was silenced (Po0.05) (Figure 4C and D).
Although LPA was shown to drive the expression of NET1 in the
presence of the RhoA inhibitor C3 exoenxyme (Figure 4A), these cells
had 91 and 96% reduced migratory and invasive capabilities in
comparison with cells treated with LPA alone (Po0.05) (Figure 4C
and D). Treatment with C3 exoenzyme alone resulted in 90% reduced
m i g r a t i o na n d8 6 %r e d u c e di n v a s i o ni nc o m p a r i s o nw i t hc o n t r o lc e l l s
(Po0.05) (Figure 4C and D).
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Figure 2 Knockdown of Net1 mRNA expression results in decreased AGS cell migration and invasion. (A) The effect of RNAi-mediated NET1
knockdown on AGS cell migration using a wound-healing assay in comparison with control AGS cells. Cells were treated with targeting or non-targeting
siRNA for 48h before the wound-healing assay. Cell migration was measured 24h after the ‘wound’. Bar: 200mm. (B) Graphical representation of the effect
of NET1 siRNA on wound healing. (C) The in vitro migratory capacity of control and NET1 knockdown cells using trans-well migration chambers. Cells were
treated with targeting or non-targeting siRNA for 48h before the migration assay, equal numbers of cells (5 10
4) were added to the chambers to
determine the effect of knockdown on migration over 24h. (D) The in vitro invasive ability of control and NET1 knockdown cells using trans-well Matrigel
invasion chambers. Cells were treated with targeting or non-targetting siRNA for 48h before the migration assay, equal numbers of cells (5 10
4) were
added to the trans-well chambers to determine the effect of knockdown on invasion over 24h. (*Po0.05). Error bars represent standard deviation of
triplicate experiments.
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Figure 4 Lysophosphatidic acid (LPA)-induced NET1 expression drives AGS cell invasion by RhoA activation. (A) Effect of LPA, NET1 siRNA and C3
exoenzyme on NET1 mRNA expression. Cells were treated with siRNA for 48h before treatment with or without LPA or C3 exoenzyme, 4h after which
cells were lysed and analysed by real-time PCR. Error bars represent the standard deviation of triplicate experiments. (B) Western blot analysis showing the
effect of LPA, NET1 siRNA and C3 exoenzyme on levels of ‘active’ and total RhoA and b-actin. Cells were treated with siRNA for 48h before treatment
with or without LPA or C3, 4h after which cells were lysed and analysed bya western immunoblot. All immunoblot analysis was repeated in triplicate.
(C) The in vitro migration of AGS cells treated with LPA, NET1 siRNA and C3 exoenzyme. Cells were treated with siRNA for 48h before treatment with or
without LPA or C3, 24h after which the effect on migration was assessed. Error bars represent the standard deviation of triplicate experiments. (D) The
effect of LPA, NET1 siRNA and C3 exoenzyme on the in vitro invasion of AGS cells. Cells were treated with siRNA for 48h before treatment with or
without LPA or C3, 24h after which the effect on invasion was assessed. Error bars represent the standard deviation of triplicate analysis (*Po0.05).
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mediated gastric cancer cell migration and invasion
Having demonstrated a role for NET1 in mediating invasion, the
effect of NET1 on cytoskeletal rearrangements was investigated.
Cytochalasin D, an inhibitor of actin filament rearrangement
significantly inhibited LPA-induced AGS cell migration and
invasion by 67 and 84%, respectively (Po0.05) (Figure 5A and
B). The invasion of control cells was also significantly reduced by
46% in the presence of CyD (Po0.05) (Figure 5B). Cytochalasin D
reduced the migration of control cells, although this reduction was
not statistically significant (Figure 5A). Control cells and cells
treated with LPA displayed well-defined actin filament structures
(Figure 6A and B). Knockdown of NET resulted in cell rounding
and a loss of definition in the actin cytoskeleton (Figure 6C) in
comparison with cells treated with nonspecific siRNA (Figure 5A).
Cells treated with LPA in which NET1 knockdown had been
achieved also appeared round with less actin cytoskeleton
organisation than control cells (Figure 6D).
DISCUSSION
We have previously identified NET1 as being upregulated in GA
and to participate in gastric cancer cell proliferation and invasion
(Leyden et al, 2006). In this current study, our aim was to further
characterise the mechanisms underpinning NET1-mediated gastric
cancer cell invasion (Figure 7).
Neuroepithelial cell transforming gene 1 is a GEF and an
activator of RhoA (Leyden et al, 2006). Rho proteins, once
activated, stimulate signalling in multiple pathways by binding to
downstream effector proteins, modulating their activities and
thereby regulating a range of cellular processes. Rho-family
proteins are regulators of the actin cytoskeleton, cell-cycle progres-
sion and gene transcription, and have been implicated in cellular
processes such as adhesion and migration, cellular morphogenesis
and polarisation (Hall, 1998; Evers et al, 2000; Sahai and Marshall,
2002; Raftopoulou and Hall, 2004).
Using an RNAi-based approach, NET1 was shown to activate
RhoA with knockdown of NET1 inhibiting the activation of RhoA
by 84% (Figure 1C and D). A second siRNA set was used to
confirm NET1-mediated activation of RhoA, thereby ruling out off
target effects (Supplementary Figure 2). Interestingly, NET1
knockdown resulted in a decrease in total RhoA levels, thereby
suggesting that as well as regulating RhoA activation, NET1 may
play a role in RhoA transcription. This is the first report that NET1
drives the activation of RhoA in GA. This finding strengthens the
role of RhoA in gastric cancer and furthermore elaborates on the
biology of NET1, a protein whose role in the disease is not yet fully
understood. Interestingly, NET1 knockdown did not result in a change
in the levels of either RhoB or RhoC (Supplementary Figure 3),
thereby supporting its role as a RhoAspecific exchange factor in
AGS cells.
Because of the established role of RhoA in cell migration and
invasion (Itoh et al, 1999; Somlyo et al, 2000; Ridley, 2001), the
effect of NET1 knockdown and therefore reduced levels of active
RhoA, on these cellular processes in AGS cells was investigated. As
expected, knockdown of NET1 resulted in a significant decrease in
gastric cancer cell migration, as assed using the in vitro wound-
healing assay (Figure 2A and B). The importance of NET1 in
tumour cell chemotaxis was further demonstrated using the trans-
well system, whereby AGS cells, in which NET1 knockdown has
been achieved, were shown to be less migratory and invasive
in vitro (Figure 2C and D). These data highlight the importance of
RhoA biology in the gastric cancer invasive programme as well as
establishing the role of NET1 in this setting.
Rho activation is frequently mediated through various cell-
surface receptors, including the tyrosine kinase, cytokine and
adhesion receptors and also the G-protein-coupled receptors
(Kjoller and Hall, 1999; Dorsam and Gutkind, 2007). Lysopho-
sphatidic acid is a well-established driver of RhoA activation and
has been shown to drive RhoA-mediated cytoskeletal rearrange-
ment events (Hart et al, 1998; Mao et al, 1998; Mills and
Moolenaar, 2003). Lysophosphatidic acid is known to promote
the migration of colorectal cancer cells and to furthermore drive
their secretion of proangiogenic factors such as VEGF, which is
essential for metastasis (Shida et al, 2003). In this study, LPA was
shown to drive the expression of NET1 mRNA and protein in a
dose-dependent manner (Figure 3A and B). Although the role of
LPA in transcription remains to be fully understood, reports
suggest that LPA-induced gene expression is mediated through
peroxisome proliferator-activated receptor, a transcriptional factor
identified as an intracellular LPA receptor (McIntyre et al, 2003).
Furthermore, we have previously shown that NET1 mRNA
expression is also driven by treatment with TNFa (Leyden et al,
2006). Although not explored in this study, the potential relation-
ship between TNFa and LPA in driving NET1 mRNA transcription
remains to be established. Indeed treatment with TNFa has been
shown to drive the expression of LPA receptor mRNA, which is
one mechanism worth exploring in the future (Zhao et al, 2008).
As expected, treatment with LPA resulted in an increase in the
levels of active RhoA (Figure 4B). Cells treated with LPA were
significantly more migratory and invasive than control cells
(Figures 3C, D and 4C, D). Although LPA resulted in a 10-fold
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Figure 5 Lysophosphatidic acid (LPA)-mediated cell invasion occurs by
cytoskeletal rearrangement events. The effect of cytochalasin D (CyD) on
(A); the in vitro migration of AGS gastric cancer cells treated with LPA,
NET1 siRNA or C3 exoenzyme, and (B) the in vitro invasion of these cells.
Cells were treated with siRNA for 48h before treatment with or without
LPA, C3 or CyD, 24h after which the effects on invasion and migration
were assessed (*,
zPo0.05). Error bars represent standard deviation of
triplicate experiments.
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sincrease in NET1 mRNA levels, this did not translate into a 10-fold
increase in migration and invasion, suggesting that NET1 protein
levels may be at a plateau in these cells. Knockdown of NET1 was
shown to inhibit LPA-induced activation of RhoA (Figure 4B) and
furthermore LPA-induced cell migration and invasion (Figure 4C
and D). Interestingly, the level of active RhoA in these cells was
similar to control cells, yet their invasion and migration was
reduced, demonstrating that NET1 is not essential for LPA-
mediated activation of RhoA, as well as suggesting that NET1 may
mediate migration and invasion through other mechanisms
besides RhoA. Inhibition of RhoA activation with C3 exoenzyme
did not affect LPA-driven NET1 expression and furthermore C3
exoenzyme alone had no effect on NET1 expression (Figure 4A).
Taken together, these data show that NET1 expression and activity
lie upstream of RhoA biology and that LPA is driving RhoA
activation through NET1. Although LPA was shown to increase the
expression of NET1 in the presence of C3 exoenzyme (Figure 4A),
these cells had reduced levels of migration and invasion (Figure 4C
and D). As well as highlighting the importance of NET1 and RhoA
in cell invasion, these data demonstrate that both NET1 and RhoA
bioactivities are essential in LPA-induced gastric cancer cell
migration and invasion. Furthermore, we have shown that NET1
inhibition is as potent at curbing cell migration and invasion as a
RhoA inhibitor. These data firmly establish the role of enhanced
NET1 expression in this disease, whereby NET1 is of key
importance in gastric cancer cell invasion.
Further to our data demonstrating that LPA drives tumour cell
invasion through both NET1 and RhoA, we next investigated the
role of the cytoskeleton in these processes. Regulation of the
cytoskeleton is a major function of RhoA activity (Hall, 1998;
Matsui et al, 1998). Cytochalasin D was used in these studies.
Cytochalasin D is a mycotoxin that inhibits both the association
and dissociation of actin filament subunits by causing disruption
of actin filaments and furthermore the inhibition of actin
polymerisation (Goddette and Frieden, 1986). Treatment with
CyD caused reduced migration and invasion of AGS cancer cells
(Figure 5A and B). Lysophosphatidic acid-induced cell migration
and invasion were dramatically reduced with CyD treatment
(Figure 5A and B). These data support our hypothesis that LPA-
induced chemotaxis of AGS gastric cancer cells occurs by
cytoskeletal rearrangement events, which are mediated at least in
part by NET1.
We have shown that LPA-mediated cell invasion involves
increased NET1 expression and RhoA activation. To further
elucidate the underlying mechanism promoting cell invasion, the
effect of various treatments on the actin cytoskeleton were
Control
siRNA LPA + siRNA
LPA
AB
CD
Figure 6 NET1 knockdown blocks the organisation of the actin cytoskeleton. Fluorescence microscopy of F-actin formation in (A) control AGS cells,
(B) cells treated with LPA, (C) cells in which NET1 knockdown was achieved and (D) cells treated with LPA and NET1 siRNA. Cells were treated with
siRNA for 48h before treatment with or without LPA, 4h after which the effect on actin polymerisation was assessed. F-actin was detected using TRITC-
conjugated phalloidin (green). Nuclei were counter stained using propidium iodide (orange). Bar 40mm.
LPA
NET1
Cell migration Cell invasion
Cytochalasin D
C3 Exoenzyme
RhoAlatent
RhoAactive
Cytoskeletal
rearrangement
Figure 7 Summary of the mechanism of NET1-mediated tumour
migration and invasion. In this study lysophosphatidic acid (LPA) was shown
to drive the expression of NET1, which increased the activation of RhoA
(a process that was inhibited by C3 exoenzyme). Knockdown of NET1 was
shown to reduce the levels of active RhoA and also a loss in the
organisation of the cytoskeletal architecture. Knockdown of NET1
furthermore resulted in a decrease in the levels of tumuor cell migration
and invasion.
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sinvestigated as Rho proteins are known key mediators of the actin
organisation (Van Aelst and D’Souza-Schorey, 1997; Ellis and
Mellor, 2000). Control AGS cells demonstrated defined actin
filament organisation (Figure 6A). Upon treatment with LPA, these
filaments became more pronounced and cells appeared elongated
and stretched (Figure 6B). Lysophosphatidic acid is known to
mediate actin cytoskeletal changes by Rho proteins and further-
more to facilitate cell migration (Jalink et al, 1994; Van Leeuwen
et al, 2003). Cells in which NET1 knockdown had been achieved
failed to demonstrate the organisation of actin filaments observed
in control or LPA-treated cells (Figure 6C). These cells have been
shown to be less migratory and invasive than control cells (Figure
4C and D), suggesting that NET1 mediates gastric cancer cell
invasion through cytoskeletal-dependent events.
This study further elaborates on the role of NET1, a novel
GA-associated GEF in the disease. We have previously shown that
NET1 is enhanced in gastric cancer tissue in comparison with
normal tissue (Leyden et al, 2006) and this study further elucidates
the mechanism by which NET1 mediates the progression of the
disease. We have shown that NET1 is a key player in LPA-induced
activation of RhoA and the subsequent migration and invasion of
gastric tumour cells. NET1 inhibition was as effective at reducing
cell invasion as treatment with the RhoA inhibitor, C3 exoenzyme
or the inhibitor of cytoskeletal rearrangement CyD, highlighting its
importance in this setting. As NET1 is important to the invasive
phonotype, we therefore propose that NET1 is an ideal potential
therapeutic target in this disease.
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